The Study
Tophi reduction: ultrasound imaging and correlation with plasma levels of uric acid in patients undergoing treatment for tophaceous gout.
This study watched 11 people with gout over time and noticed that when their uric acid went down, their lumps (tophi) also got smaller. But it didn’t test if lowering uric acid made the lumps shrink — maybe they ate better or lost weight, and that helped instead.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Doctors gave gout patients medicine to lower uric acid and used ultrasound to see if the painful lumps (tophi) got smaller over time.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 544 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this shows that keeping uric acid low for years can slowly dissolve gout lumps, helping patients avoid joint damage.
- 2Uric acid dropped from 8.39 to 4.92 mg/dL; tophi grew a bit at first, then shrank by 23% on average after 3–4 years, with stronger uric acid drops linked to bigger lumps shrinking.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Reumatismo
Year
2019
Authors
A. J. Ferrari, A. Fernandes, R. Agustinelli, H. Seike, E. Fernandes
Related Content
Claims (6)
In men with tophaceous gout receiving treatment to lower uric acid levels over nearly four years, the size of uric acid crystal deposits measured by ultrasound decreased by 23% on average, with the largest reduction occurring after the fourth year of treatment.
Ultrasound accurately measures the size of uric acid crystals in joints of people with tophaceous gout, and these measurements show a consistent decrease in crystal volume after 3 to 4 years of treatment that lowers uric acid levels.
In patients with tophaceous gout, serum uric acid levels dropped from an average of 8.39 mg/dL to 4.92 mg/dL after 3.8 years of uric acid-lowering therapy, though responses varied widely among individuals.
In some patients with tophaceous gout, tophi grow larger for the first 1 to 3 years of treatment before they start to shrink, reflecting a temporary phase of crystal movement or inflammation before breakdown.
In patients with tophaceous gout, greater reductions in blood uric acid levels are consistently linked to greater reductions in tophi size over time, with a very strong statistical relationship observed in those with measurable changes.
A quick drop in blood uric acid levels causes urate crystals to move through joint membranes and activate inflammation.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.